<DOC>
	<DOCNO>NCT00104429</DOCNO>
	<brief_summary>This study 96-week study design evaluate safety efficacy GW873140 combination Combivir HIV infect , untreated subject .</brief_summary>
	<brief_title>GW873140 In Combination With Combivir In HIV Infected Subjects</brief_title>
	<detailed_description>A Phase IIb , 96 week , randomize , partially double-blinded , multicenter , parallel group , repeat dose study evaluate safety , tolerability , pharmacokinetics antiviral effect GW873140 combination Combivir ( lamivudine zidovudine ) upon select immunological virological marker HIV-1 infection antiretroviral therapy naive adult</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion criterion : HIV infect subject . Females must either nonchildbearing age , negative pregnancy test . All subject participate study counsel practice safe sex use proven double barrier method contraception throughout study . Screening lab result plasma HIV1 RNA great equal 10,000 copies/mL CD4 cell count great equal 100 cells/mm3 . Have CC Chemokine Receptor5tropic ( R5tropic ) virus base viral tropism test screen visit . Have drug resistance mutation HIV1 Reverse Transcriptase base resistance test screen visit . Be treatmentnaive , define less equal 2 week treatment protease inhibitor ( PI ) nucleoside reverse transcriptase inhibitor/nucleotide reverse transcriptase inhibitor ( NRTI/ NtRTI ) , less equal 7 day therapy nonnucleoside reverse transcriptase inhibitor ( NNRTI ) . Prior treatment entry inhibitor , attachment inhibitor , fusion inhibitor ( experimental approve ) allow . Be able understand follow protocol requirement , instruction protocolstated restriction . Signed date write informed consent prior study entry . Exclusion criterion : Detection CXC Receptor4tropic ( X4tropic ) virus , base viral tropism test screening . Any drug resistance mutation HIV1 Reverse Transcriptase base resistance test screen visit . Active Class C AIDSdefining illness . Laboratory abnormality screen . Significant blood loss prior study start . Pregnant breastfeed woman . Additional qualify criterion determine physician .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>therapy naive</keyword>
</DOC>